L. Morgan Frisoli

Morgan Frisoli is counsel in the firm’s ERISA & Executive Compensation practice, and advises both public and private clients on a wide range of compensation and benefit matters.

Morgan advises clients on the design, drafting and administration of incentive compensation, employment, severance, change in control and deferred compensation arrangements, including associated tax (including Section 409A), accounting and securities law implications. He also assists public companies with compensation-related public disclosures for proxy filings and other applicable securities filings.

Morgan plays an active role in corporate transactions, representing both buyers and sellers in connection with the compensation and benefits aspects of transactions, including pre-signing negotiations, executive and equity compensation matters (including Section 280G – the golden parachute rules), and post-closing employee integration matters.

• Keryx Biopharmaceuticals, Inc. in its merger with Akebia Therapeutics, Inc., with an implied pro forma equity value of approximately $1.3 billion.
• Unum Therapeutics and Neon Therapeutics on their initial public offerings.
• KIND LLC, in assistance with equity compensation matters following its strategic partnership with Mars.
• Several private equity and venture capital firms in their acquisition and sale of portfolio companies.

Morgan is a member of the Massachusetts and Boston Bar Associations.

Dividing Value in the Sale of Mixed Goods and Services for International Tax, The Practical Tax Lawyer, May 2017